Lv7
4410 积分 2022-07-07 加入
Exploring the landscape of targetable alterations in patients with glioblastoma
1天前
已完结
NICE rejects breast cancer drug over cost
4天前
已完结
An imprecise label in the era of precision medicine: labelling and access for daraxonrasib, the first pan-RAS inhibitor approval
5天前
已完结
Exercise therapy in cancer prevention and treatment
6天前
已完结
Exploring the immunological effects of antibody–drug conjugates
7天前
已完结
Universal Germline Genetic Testing after a Diagnosis of Cancer
8天前
已完结
Exploring the immunological effects of antibody–drug conjugates
8天前
已完结
Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial
9天前
已完结
Targeting RAS in pancreatic cancer
10天前
已完结
A modular framework for antibody–drug conjugate biomarkers
11天前
已完结
皖公网安备34019202002308
